Gerald Anthony Reynolds Net Worth

The estimated Net Worth of Gerald Anthony Reynolds is at least $11.6 Thousand dollars as of 27 May 2022. Mr Reynolds owns over 3,994 units of Applied Genetic Technologies Corp stock worth over $8,192 and over the last 3 years he sold AGTC stock worth over $3,395.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr Reynolds AGTC stock SEC Form 4 insiders trading

Mr has made over 1 trades of the Applied Genetic Technologies Corp stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 3,994 units of AGTC stock worth $3,395 on 27 May 2022.

The largest trade he's ever made was selling 3,994 units of Applied Genetic Technologies Corp stock on 27 May 2022 worth over $3,395. On average, Mr trades about 999 units every 0 days since 2021. As of 27 May 2022 he still owns at least 21,006 units of Applied Genetic Technologies Corp stock.

You can see the complete history of Mr Reynolds stock trades at the bottom of the page.

Mr. Gerald Anthony Reynolds biography

Gerald Anthony Reynolds is the Chief Accounting Officer, Principal Accounting Officer & Treasurer at Applied Genetic Technologies Corp.

What's Mr Reynolds's mailing address?

Gerald's mailing address filed with the SEC is C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE #10, ALACHUA, FL, 32615.

Insiders trading at Applied Genetic Technologies Corp

Over the last 11 years, insiders at Applied Genetic Technologies Corp have traded over $12,578,298 worth of Applied Genetic Technologies Corp stock and bought 760,946 units worth $8,946,827 . The most active insiders traders include Plc Gsk, Edward Hurwitz, and Ventures, Inc. Med Immune. On average, Applied Genetic Technologies Corp executives and independent directors trade stock every 89 days with the average trade being worth of $18,318. The most recent stock trade was executed by Stephen W Potter on 30 June 2022, trading 8,070 units of AGTC stock currently worth $6,214.

What does Applied Genetic Technologies Corp do?

Applied Genetic Technologies Corp. (AGTC) is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTC's most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3). Its preclinical programs build on the Company's industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders. In recent years AGTC has entered into strategic partnerships with companies including Otonomy, a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, and Bionic Sight, an innovator in the emerging field of optogenetics and retinal coding.

Complete history of Mr Reynolds stock trades at Applied Genetic Technologies Corp

Applied Genetic Technologies Corp executives and stock owners

Applied Genetic Technologies Corp executives and other stock owners filed with the SEC include:

• Susan B. Washer,
  Pres, CEO & Director
• Stephen W. Potter,
  VP & Chief Bus. Officer
• Dr. Abraham Scaria Ph.D.,
  Chief Scientific Officer
• Gerald Anthony Reynolds,
  Chief Accounting Officer, Principal Accounting Officer & Treasurer
• Jonathan I. Lieber M.B.A.,
  Chief Financial Officer
• Dr. Terence R. Flotte M.D.,
  Co-Founder
• Dr. Richard Jude Samulski Ph.D.,
  Co-Founder
• Dr. William W. Hauswirth,
  Co-Founder & Member of Ophthalmology Scientific Advisory Board
• Dr. Barry J. Byrne M.D., Ph.D.,
  Co-Founder
• Dr. Nicholas Muzyczka,
  Co-Founder
• Edward Hurwitz,
  Director
• Michael H. Goldstein,
  Chief Medical Officer
• Jeffrey D. Chulay,
  V.P. & Chief Medical Officer
• Bruce Peacock,
  Director
• Ivana Magovcevic Liebisch,
  Director
• Lawrence E Bullock,
  Chief Financial Officer
• Arnold L Oronsky,
  Director
• Anne Vanlent,
  Director
• Scott Koenig,
  Director
• Mark S Shearman,
  Chief Scientific Officer
• James Rosen,
  Director
• Brian Krex,
  General Counsel
• Patrick Johan Hendrik Stich...,
  
• William A. Sullivan,
  Chief Financial Officer
• Abraham Scaria,
  Chief Scientific Officer
• Stephen W Potter,
  Chief Business Officer
• William Aliski,
  Director
• Theresa Heah,
  Chief Medical Officer
• Matthew Feinsod,
  Exec. VP, Global Strat. & Dev.
• Jill Carroll,
  Director
• Daniel L Menichella,
  V.P. & Chief Business Officer
• David R. Knop,
  Director, Process Development
• Plc Gsk,
  10% owner
• Ventures, Inc. Med Immune,
  10% owner
• Partners Viii Lp Inter West...,
  
• Samuel Wu,
  Director
• Partners Viii, L.P.Champsi ...,
  
• Susan B. Washer,
  President and CEO
• Jonathan I Lieber,
  Chief Financial Officer
• Gerald Anthony Reynolds,
  Chief Accounting Officer
• Yehia Hashad,
  Director
• Hope D Oyley Gay,
  General Counsel
• James A. Jr. Robinson,
  Director
• Susan Schneider,
  Chief Medical Officer